Tom Huxford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tom Huxford has a total of 177 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin G. Bitler
Department of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado
24 shared publications - Candyd Lace R. Velasquez
Department of Biology, San Diego State University, San Diego, California
24 shared publications - Carrie D. House
Biology Department, San Diego State University, San Diego, CA 92106, USA
24 shared publications - Denay Stevenson
Department of Biology, San Diego State University, San Diego, California. 1
24 shared publications - Emily Kogan
Department of Molecular, Cell and Developmental Biology, University of California Santa Cruz, Santa Cruz, USA
24 shared publications - Emily M. Mu
Department of Cell Biology, Van Andel Institute, Grand Rapids, MI 49503, USA
24 shared publications
Latest Publications
- Open Access
Cryo-EM reveals alternative modes of dimerization driving activation of IKK
The inhibitor of κB kinase (IKK) complex integrates diverse cellular inflammatory responses, and induces transcription factor NF-κB. The molecular mechanism by which IKK becomes catalytically active in response to signaling remains unclear despite structural knowledge of the individual IKK1/α, IKK2/β, and NEMO/IKKγ protein components within its hetero-oligomeric assembly. Cryo-EM of the IKK2/β homodimer bound to an associating NEMO/IKKγ protein fragment, reveals multiple conformers. Mutual exclusivity of dimeric conformers, canonical versus alternate, is reflected in and dependent upon order-to-disorder transition of the canonical 6-helical bundle dimerization interface. Correlation of this unusual structural plasticity of IKK2/β with its biochemical and cellular activities suggests mechanistic possibilities for how association with its partner scaffold protein NEMO/IKKγ and polyubiquitin chains might dictate catalytic activation of IKK through distinct IKK2/β conformers.
Open AccessCryo-EM reveals alternative modes of dimerization driving activation of IKK
The inhibitor of κB kinase (IKK) complex integrates diverse cellular inflammatory responses, and induces transcription factor NF-κB. The molecular mechanism by which IKK becomes catalytically active in response to signaling remains unclear despite structural knowledge of the individual IKK1/α, IKK2/β, and NEMO/IKKγ protein components within its hetero-oligomeric assembly. Cryo-EM of the IKK2/β homodimer bound to an associating NEMO/IKKγ protein fragment, reveals multiple conformers. Mutual exclusivity of dimeric conformers, canonical versus alternate, is reflected in and dependent upon order-to-disorder transition of the canonical 6-helical bundle dimerization interface. Correlation of this unusual structural plasticity of IKK2/β with its biochemical and cellular activities suggests mechanistic possibilities for how association with its partner scaffold protein NEMO/IKKγ and polyubiquitin chains might dictate catalytic activation of IKK through distinct IKK2/β conformers.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
Supplementary Table 1 from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
Supplementary Table 1 from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary References from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
Supplementary References from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary References from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
Supplementary References from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
Public databases used in this study
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
Public databases used in this study
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
TWEAK and Fn14 are associated with worse outcomes in ovarian cancer.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
TWEAK and Fn14 are associated with worse outcomes in ovarian cancer.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
TWEAK has minimal effect on proliferation or apoptosis of ovarian cancer cells
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
TWEAK has minimal effect on proliferation or apoptosis of ovarian cancer cells
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
Mouse TWEAK activates NF-κB pathway in human ovarian cancer cells.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
Mouse TWEAK activates NF-κB pathway in human ovarian cancer cells.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
Reagent and Manufacturer Order Information.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
Reagent and Manufacturer Order Information.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Data from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
Disease recurrence in high-grade serous ovarian cancer may be due to cancer stem–like cells (CSC) that are resistant to chemotherapy and capable of reestablishing heterogeneous tumors. The alternative NF-κB signaling pathway is implicated in this process; however, the mechanism is unknown. Here we show that TNF-like weak inducer of apoptosis (TWEAK) and its receptor, Fn14, are strong inducers of alternative NF-κB signaling and are enriched in ovarian tumors following chemotherapy treatment. We further show that TWEAK enhances spheroid formation ability, asymmetric division capacity, and expression of SOX2 and epithelial-to-mesenchymal transition genes VIM and ZEB1 in ovarian cancer cells, phenotypes that are enhanced when TWEAK is combined with carboplatin. Moreover, TWEAK in combination with chemotherapy induces expression of the CSC marker CD117 in CD117− cells. Blocking the TWEAK–Fn14–RelB signaling cascade with a small-molecule inhibitor of Fn14 prolongs survival following carboplatin chemotherapy in a mouse model of ovarian cancer. These data provide new insights into ovarian cancer CSC biology and highlight a signaling axis that should be explored for therapeutic development.Implications:This study identifies a unique mechanism for the induction of ovarian cancer stem cells that may serve as a novel therapeutic target for preventing relapse.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
Disease recurrence in high-grade serous ovarian cancer may be due to cancer stem–like cells (CSC) that are resistant to chemotherapy and capable of reestablishing heterogeneous tumors. The alternative NF-κB signaling pathway is implicated in this process; however, the mechanism is unknown. Here we show that TNF-like weak inducer of apoptosis (TWEAK) and its receptor, Fn14, are strong inducers of alternative NF-κB signaling and are enriched in ovarian tumors following chemotherapy treatment. We further show that TWEAK enhances spheroid formation ability, asymmetric division capacity, and expression of SOX2 and epithelial-to-mesenchymal transition genes VIM and ZEB1 in ovarian cancer cells, phenotypes that are enhanced when TWEAK is combined with carboplatin. Moreover, TWEAK in combination with chemotherapy induces expression of the CSC marker CD117 in CD117− cells. Blocking the TWEAK–Fn14–RelB signaling cascade with a small-molecule inhibitor of Fn14 prolongs survival following carboplatin chemotherapy in a mouse model of ovarian cancer. These data provide new insights into ovarian cancer CSC biology and highlight a signaling axis that should be explored for therapeutic development.Implications:This study identifies a unique mechanism for the induction of ovarian cancer stem cells that may serve as a novel therapeutic target for preventing relapse.
- 11 July 2025
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 64 (15) , 3237-3247
Incorporating Metal–Ligand and Salt-Bridge Interactions in the Design of Protein Heterodimers
The design of chemically controlled asymmetric protein-protein interfaces will further enhance the building of precise protein-based biomaterials. Driving protein-protein interactions through engineered metal-ligand coordination and salt-bridge formation enables the reversible association of two unique binding partners. Creation of precise biomaterial is enhanced through the temporal and chemical control afforded by metal-controlled heterodimeric proteins. In addition, heterodimers enable the specific association of different passenger proteins expressed as fusions to the heterodimeric binding partners. To increase the versatility of protein-based tools, we converted a previously engineered metal-controlled homodimer into a metal-controlled heterodimer. To promote specificity of the heterodimer complex and prevent self-association, it was necessary to incorporate elements of positive and negative design, which was achieved through the incorporation of a cross-interface electrostatic interaction, as well as modifications to hydrophobic contacts at the protein-protein interface. The resulting metal-controlled heterodimer binds with low micromolar affinity, and the crystal structures indicate the presence of the designed dual-interaction motifs at the protein-protein interface.
- 11 July 2025
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 64 (15) , 3237-3247
Incorporating Metal–Ligand and Salt-Bridge Interactions in the Design of Protein Heterodimers
The design of chemically controlled asymmetric protein-protein interfaces will further enhance the building of precise protein-based biomaterials. Driving protein-protein interactions through engineered metal-ligand coordination and salt-bridge formation enables the reversible association of two unique binding partners. Creation of precise biomaterial is enhanced through the temporal and chemical control afforded by metal-controlled heterodimeric proteins. In addition, heterodimers enable the specific association of different passenger proteins expressed as fusions to the heterodimeric binding partners. To increase the versatility of protein-based tools, we converted a previously engineered metal-controlled homodimer into a metal-controlled heterodimer. To promote specificity of the heterodimer complex and prevent self-association, it was necessary to incorporate elements of positive and negative design, which was achieved through the incorporation of a cross-interface electrostatic interaction, as well as modifications to hydrophobic contacts at the protein-protein interface. The resulting metal-controlled heterodimer binds with low micromolar affinity, and the crystal structures indicate the presence of the designed dual-interaction motifs at the protein-protein interface.